23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › OCULAR THERAPEUTIX INC. › 2023-2024

OCULAR THERAPEUTIX INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and OCULAR THERAPEUTIX INC.’s Form 8-K, filed June 14, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 6Ballot items
  • 138Asset managers, any item
  • 844Fund votes
  • June 12, 2024Meeting date

Results at a glance

Meeting of June 12, 2024: 6 items on OCULAR THERAPEUTIX INC.’s Form 8-K, filed June 14, 2024: 2 elected · 4 approved.

Dissent

No notable dissent.

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore OCULAR THERAPEUTIX INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by OCULAR THERAPEUTIX INC.

These tallies are OCULAR THERAPEUTIX INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 14, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

OCULAR THERAPEUTIX INC. — official shareholder meeting results, meeting held June 12, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Adrienne L. Graves, Ph.D. 85,368,917---- 389,15535,036,868 99.5%Elected—
Elect Director: Charles Warden 78,505,842---- 7,252,23035,036,868 92%Elected—
(2) The Company's stockholders approved a non-binding, advisory proposal regarding the compensation of the Company's named executive officers. 76,321,5099,265,164171,399 --35,036,868 89%Approved—
(3) The Company's stockholders approved Amendment No. 3 to increase the number of shares of common stock of the Company issuable under the 2021 Stock Incentive Plan by 7,000,000 shares. 84,021,2771,650,94785,848 --35,036,868 98%Approved—
(4) The Company's stockholders approved the proposal to amend the Company's Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 200,000,000 to 400,000,000. 112,604,8138,024,680165,447 ---- 93%Approved—
(5) The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2024. 119,634,478859,430301,032 ---- 99.3%Approved—

Source: OCULAR THERAPEUTIX INC., Form 8-K, filed with the SEC on June 14, 2024 — read the filing on EDGAR.

How asset managers voted at the OCULAR THERAPEUTIX INC. 2023-2024 meeting

138 asset managers disclosed a vote on at least one OCULAR THERAPEUTIX INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Adrienne L. Graves, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

99.5% Majority: yes · of votes cast

FOR 99.5%
FOR: 85,368,917WITHHELD: 389,155
Details: description as filed, official tally, votes by 39 asset managers

Description as filed by funds: To elect two Class I directors, each to serve until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Adrienne L. Graves, Ph.D.

OCULAR THERAPEUTIX INC.’s own tally for this item (“Elect Director: Adrienne L. Graves, Ph.D.”): 85,368,917 for, 389,155 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(1) The Company's stockholders elected Adrienne L. Graves, Ph.D. and Charles Warden as Class I directors to serve until the 2027 Annual Meeting of Stockholders, each such director to hold office until her or his successor has been duly elected and qualified.”
Support: 99.5% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 39 asset managers below reported 14,390,145 for.

FOR
FOR: 14,390,145
Largest asset managers voting on “To elect two Class I directors, each to serve until the 2027 Annual Meeting of Stockholders and until his or h” at OCULAR THERAPEUTIX INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard7,022,8090 00For
Fidelity2,186,7300 00For
TIAA824,6200 00For
T. Rowe Price774,8750 00For
FRANKLIN STRATEGIC SERIES750,1000 00For
Invesco519,1670 00For
BlackRock505,7530 00For
Charles Schwab316,4710 00For
Equitable311,4960 00For
QUANTITATIVE MASTER SERIES LLC176,9120 00For
State Street157,2120 00For
PARADIGM FUNDS140,0000 00For
Lincoln Financial92,9000 00For
1290 Funds80,1110 00For
John Hancock66,7030 00For
AIG/SunAmerica56,9810 00For
Goldman Sachs48,6930 00For
Pacific Life38,6850 00For
Voya36,9560 00For
Global X36,1970 00For
Brighthouse34,2960 00For
ProShares34,0270 00For
Nationwide31,3950 00For
Bridge Builder Trust21,6190 00For
SEI18,4000 00For

Showing the 25 largest of 39 asset managers. All 39 are in the interactive database (link above).

Elect Director: Charles Warden

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%
FOR: 78,505,842WITHHELD: 7,252,230
Details: description as filed, official tally, votes by 39 asset managers

Description as filed by funds: To elect two Class I directors, each to serve until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Charles Warden

OCULAR THERAPEUTIX INC.’s own tally for this item (“Elect Director: Charles Warden”): 78,505,842 for, 7,252,230 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(1) The Company's stockholders elected Adrienne L. Graves, Ph.D. and Charles Warden as Class I directors to serve until the 2027 Annual Meeting of Stockholders, each such director to hold office until her or his successor has been duly elected and qualified.”
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 39 asset managers below reported 13,479,517 for, 910,628 withheld.

FOR
FOR: 13,479,517WITHHOLD: 910,628
Largest asset managers voting on “To elect two Class I directors, each to serve until the 2027 Annual Meeting of Stockholders and until his or h” at OCULAR THERAPEUTIX INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard7,022,8090 00For
Fidelity2,186,7300 00For
TIAA824,6200 00For
T. Rowe Price774,8750 00For
FRANKLIN STRATEGIC SERIES00 0750,100Withhold
Invesco519,1670 00For
BlackRock505,7530 00For
Charles Schwab316,4710 00For
Equitable206,5460 0104,950Mixed
QUANTITATIVE MASTER SERIES LLC176,9120 00For
State Street157,1900 022For
PARADIGM FUNDS140,0000 00For
Lincoln Financial92,9000 00For
1290 Funds80,1110 00For
John Hancock66,7030 00For
AIG/SunAmerica56,9810 00For
Goldman Sachs48,6930 00For
Pacific Life38,6850 00For
Voya36,9560 00For
Global X00 036,197Withhold
Brighthouse34,2960 00For
ProShares34,0270 00For
Nationwide30,4360 0959For
Bridge Builder Trust21,6190 00For
SEI00 018,400Withhold

Showing the 25 largest of 39 asset managers. All 39 are in the interactive database (link above).

(4) The Company's stockholders approved the proposal to amend the Company's Restated Certificate of Incorporation, as…

Official resultCAPITAL STRUCTUREReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

93% Approved · of votes cast

FOR 93%
FOR: 112,604,813AGAINST: 8,024,680
Details: description as filed, official tally, votes by 39 asset managers

Description as filed by funds: To approve an amendment to our Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of our common stock from 200,000,000 shares to 400,000,000 shares.

OCULAR THERAPEUTIX INC.’s own tally for this item (“(4) The Company's stockholders approved the proposal to amend the Company's Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 200,000,000 to 400,000,000.”): 112,604,813 for, 8,024,680 against — passed, per its Form 8-K filed June 14, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(4) The Company's stockholders approved the proposal to amend the Company's Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 200,000,000 to 400,000,000.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 39 asset managers below reported 14,390,132 for, 13 against.

FOR
FOR: 14,390,132AGAINST: 13
Largest asset managers voting on “To approve an amendment to our Restated Certificate of Incorporation, as amended, to increase the number of au” at OCULAR THERAPEUTIX INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard7,022,8090 00For
Fidelity2,186,7300 00For
TIAA824,6200 00For
T. Rowe Price774,8750 00For
FRANKLIN STRATEGIC SERIES750,1000 00For
Invesco519,1670 00For
BlackRock505,7530 00For
Charles Schwab316,4710 00For
Equitable311,4960 00For
QUANTITATIVE MASTER SERIES LLC176,9120 00For
State Street157,19913 00For
PARADIGM FUNDS140,0000 00For
Lincoln Financial92,9000 00For
1290 Funds80,1110 00For
John Hancock66,7030 00For
AIG/SunAmerica56,9810 00For
Goldman Sachs48,6930 00For
Pacific Life38,6850 00For
Voya36,9560 00For
Global X36,1970 00For
Brighthouse34,2960 00For
ProShares34,0270 00For
Nationwide31,3950 00For
Bridge Builder Trust21,6190 00For
SEI18,4000 00For

Showing the 25 largest of 39 asset managers. All 39 are in the interactive database (link above).

(3) The Company's stockholders approved Amendment No. 3 to increase the number of shares of common stock of the Company…

Official resultCOMPENSATIONReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

98% Approved · of votes cast

FOR 98%
FOR: 84,021,277AGAINST: 1,650,947

Prior year: 78.6% for (June 14, 2023 meeting) ▲ 19.4 pts

Details: description as filed, official tally, votes by 39 asset managers

Description as filed by funds: To approve an amendment to the Ocular Therapeutix, Inc. 2021 Stock Incentive Plan, as amended, to increase the number of shares of common stock issuable thereunder by 7,000,000 shares.

OCULAR THERAPEUTIX INC.’s own tally for this item (“(3) The Company's stockholders approved Amendment No. 3 to increase the number of shares of common stock of the Company issuable under the 2021 Stock Incentive Plan by 7,000,000 shares.”): 84,021,277 for, 1,650,947 against — passed, per its Form 8-K filed June 14, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(3) The Company's stockholders approved Amendment No. 3 to increase the number of shares of common stock of the Company issuable under the 2021 Stock Incentive Plan by 7,000,000 shares.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 39 asset managers below reported 14,378,592 for, 11,553 against.

FOR
FOR: 14,378,592AGAINST: 11,553
Largest asset managers voting on “To approve an amendment to the Ocular Therapeutix, Inc. 2021 Stock Incentive Plan, as amended, to increase the” at OCULAR THERAPEUTIX INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard7,022,8090 00For
Fidelity2,186,7300 00For
TIAA824,6200 00For
T. Rowe Price774,8750 00For
FRANKLIN STRATEGIC SERIES750,1000 00For
Invesco519,1670 00For
BlackRock505,7530 00For
Charles Schwab316,4710 00For
Equitable311,4960 00For
QUANTITATIVE MASTER SERIES LLC176,9120 00For
State Street157,19022 00For
PARADIGM FUNDS140,0000 00For
Lincoln Financial92,9000 00For
1290 Funds80,1110 00For
John Hancock66,7030 00For
AIG/SunAmerica56,9810 00For
Goldman Sachs48,6930 00For
Pacific Life38,6850 00For
Voya36,9560 00For
Global X36,1970 00For
Brighthouse34,2960 00For
ProShares34,0270 00For
Nationwide31,3950 00For
Bridge Builder Trust21,6190 00For
SEI18,4000 00For

Showing the 25 largest of 39 asset managers. All 39 are in the interactive database (link above).

(2) The Company's stockholders approved a non-binding, advisory proposal regarding the compensation of the Company's…

Official resultFund totals may overlapCOMPENSATIONReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

89% Approved · of votes cast

FOR 89%
FOR: 76,321,509AGAINST: 9,265,164

Prior year: 70.4% for (June 14, 2023 meeting) ▲ 18.8 pts

Details: description as filed, official tally, votes by 137 asset managers

Description as filed by funds: To approve an advisory vote on named executive officer compensation.

OCULAR THERAPEUTIX INC.’s own tally for this item (“(2) The Company's stockholders approved a non-binding, advisory proposal regarding the compensation of the Company's named executive officers.”): 76,321,509 for, 9,265,164 against — passed, per its Form 8-K filed June 14, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(2) The Company's stockholders approved a non-binding, advisory proposal regarding the compensation of the Company's named executive officers.”
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 39 asset managers voting on “To approve an advisory vote on named executive officer compensation.” at OCULAR THERAPEUTIX INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard7,022,8090 00For
Fidelity2,186,7300 00For
TIAA824,6200 00For
T. Rowe Price774,8750 00For
FRANKLIN STRATEGIC SERIES0750,100 00Against
Invesco0519,167 00Against
BlackRock505,7530 00For
Charles Schwab316,4710 00For
Equitable311,4960 00For
QUANTITATIVE MASTER SERIES LLC176,9120 00For
State Street157,17141 00For
PARADIGM FUNDS140,0000 00For
Lincoln Financial92,9000 00For
1290 Funds80,1110 00For
John Hancock66,7030 00For
AIG/SunAmerica56,9810 00For
Goldman Sachs48,6930 00For
Pacific Life38,6850 00For
Voya36,9560 00For
Global X036,197 00Against
Brighthouse34,2960 00For
ProShares34,0270 00For
Nationwide30,436959 00For
Bridge Builder Trust21,6190 00For
SEI018,400 00Against

Fund voting reports, all 39 managers: 13,053,750 for, 1,336,395 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 113 asset managers voting on “To approve an advisory vote on named executive officer compensation.” at OCULAR THERAPEUTIX INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Deep Track Capital, LP9,230,7690 00For
VR Adviser, LLC7,775,7600 00For
Avoro Capital Advisors LLC7,148,9360 00For
Logos Global Management LP03,768,953 00Against
Citadel3,187,5010 00For
DELTEC ASSET MANAGEMENT LLC2,295,3330 00For
GEODE CAPITAL MANAGEMENT, LLC2,273,3740 00For
FRANKLIN ADVISERS INC02,168,284 00Against
BlackRock2,089,2129,118 00For
Octagon Capital Advisors LP1,839,6320 00For
GREAT POINT PARTNERS LLC1,728,7230 00For
State Street1,692,6764,340 00For
PERCEPTIVE ADVISORS LLC1,394,4060 00For
ACUTA CAPITAL PARTNERS, LLC1,322,8780 00For
T. Rowe Price968,0940 00For
Nuveen832,7800 00For
Artia Global Partners LP775,8850 00For
Point72704,7670 00For
Opaleye Management Inc.698,1380 00For
Northern Trust654,702530 00For
Invesco0545,524 00Against
ADAGE CAPITAL PARTNERS GP, L.L.C.375,0000 00For
Charles Schwab316,4710 00For
Wellington0242,912 00Against
Vanguard237,0140 00For

Institutional-manager reports, all 113 managers: 49,099,115 for, 7,448,644 against. Showing the 25 largest; every one is in the interactive database (link above).

(5) The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP as its independent registered…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

99.3% Approved · of votes cast

FOR 99.3%
FOR: 119,634,478AGAINST: 859,430

Prior year: 99.9% for (June 14, 2023 meeting) ▼ 0.6 pts

Details: description as filed, official tally, votes by 39 asset managers

Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP as Ocular Therapeutix's independent registered public accounting firm for the fiscal year ending December 31, 2024.

OCULAR THERAPEUTIX INC.’s own tally for this item (“(5) The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2024.”): 119,634,478 for, 859,430 against — passed, per its Form 8-K filed June 14, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(5) The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 39 asset managers below reported 14,390,123 for, 22 against.

FOR
FOR: 14,390,123AGAINST: 22
Largest asset managers voting on “To ratify the appointment of PricewaterhouseCoopers LLP as Ocular Therapeutix's independent registered public ” at OCULAR THERAPEUTIX INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard7,022,8090 00For
Fidelity2,186,7300 00For
TIAA824,6200 00For
T. Rowe Price774,8750 00For
FRANKLIN STRATEGIC SERIES750,1000 00For
Invesco519,1670 00For
BlackRock505,7530 00For
Charles Schwab316,4710 00For
Equitable311,4960 00For
QUANTITATIVE MASTER SERIES LLC176,9120 00For
State Street157,19022 00For
PARADIGM FUNDS140,0000 00For
Lincoln Financial92,9000 00For
1290 Funds80,1110 00For
John Hancock66,7030 00For
AIG/SunAmerica56,9810 00For
Goldman Sachs48,6930 00For
Pacific Life38,6850 00For
Voya36,9560 00For
Global X36,1970 00For
Brighthouse34,2960 00For
ProShares34,0270 00For
Nationwide31,3950 00For
Bridge Builder Trust21,6190 00For
SEI18,4000 00For

Showing the 25 largest of 39 asset managers. All 39 are in the interactive database (link above).

Largest OCULAR THERAPEUTIX INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 154,704,086 shares outstanding at the time of that meeting.

Fund voting reports: top OCULAR THERAPEUTIX INC. shareholders by shares voted on “To approve an advisory vote on named executive officer compensation.”, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 4.54%
2Fidelity 1.41%
3TIAA 0.53%
4T. Rowe Price 0.50%
5FRANKLIN STRATEGIC SERIES 0.48%
6Invesco 0.34%
7BlackRock 0.33%
8Charles Schwab 0.20%
9Equitable 0.20%
10QUANTITATIVE MASTER SERIES LLC 0.11%
Institutional-manager reports: top OCULAR THERAPEUTIX INC. shareholders by shares voted on “To approve an advisory vote on named executive officer compensation.”, 2023-2024
#Asset manager % of shares outstanding
1Deep Track Capital, LP 5.97%
2VR Adviser, LLC 5.03%
3Avoro Capital Advisors LLC 4.62%
4Logos Global Management LP 2.44%
5Citadel 2.06%
6DELTEC ASSET MANAGEMENT LLC 1.48%
7GEODE CAPITAL MANAGEMENT, LLC 1.47%
8FRANKLIN ADVISERS INC 1.40%
9BlackRock 1.36%
10Octagon Capital Advisors LP 1.19%

Reported OCULAR THERAPEUTIX INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

OCULAR THERAPEUTIX INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
FMR (Fidelity)31,785,634 20.55%Form 13F, quarter ended March 31, 2024
BlackRock10,556,837 6.82%Form 13F, quarter ended March 31, 2024
Vanguard Group9,163,240 5.92%Form 13F, quarter ended March 31, 2024
Citadel Advisors5,636,301 3.64%Form 13F, quarter ended March 31, 2024
Geode Capital2,486,043 1.61%Form 13F, quarter ended March 31, 2024
Morgan Stanley2,465,676 1.59%Form 13F, quarter ended March 31, 2024
State Street2,402,380 1.55%Form 13F, quarter ended March 31, 2024
Franklin Templeton2,168,313 1.40%Form 13F, quarter ended March 31, 2024
Nuveen1,213,445 0.78%Form 13F, quarter ended March 31, 2024
Northern Trust970,098 0.63%Form 13F, quarter ended March 31, 2024

Percentages above are of 154,704,086 shares outstanding, as reported by OCULAR THERAPEUTIX INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At OCULAR THERAPEUTIX INC.'s shareholder meeting held June 12, 2024, in the 2023-2024 proxy season, 138 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 844 separate fund positions. On the most widely held item on that ballot — To approve an advisory vote on named executive officer compensation. — OCULAR THERAPEUTIX INC.'s filing reports the proposal as approved, with 89% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: OCULAR THERAPEUTIX INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 14, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from OCULAR THERAPEUTIX INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

OCULAR THERAPEUTIX INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “OCULAR THERAPEUTIX (OCUL) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/ocular-therapeutix-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.